Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy)
Authors:
- Paolo A. AsciertoPAPaolo A. Ascierto
- Igor PuzanovIPIgor Puzanov
- Sanjiv S. AgarwalaSASanjiv S. Agarwala
- Carlo BifulcoCBCarlo Bifulco
- Gerardo BottiGBGerardo Botti
- Corrado CaracòCCCorrado Caracò
- Gennaro CilibertoGennaro Ciliberto
- Michael A. DaviesMDMichael A. Davies
- Reinhard DummerReinhard Dummer
- Soldano FerroneSoldano Ferrone
- Thomas F. GajewskiTGThomas F. Gajewski
- Claus GarbeClaus Garbe
Open Access
- 21 July 2018
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 16 (1) , 1-13
Abstract
Metastatic melanoma represents a challenging clinical situation and, until relatively recently, there was an absence of effective treatment options. However, in 2011, the advanced melanoma treatment landscape was revolutionised with the approval of the anti-cytotoxic T-lymphocyte-associated protein-4 checkpoint inhibitor ipilimumab and the selective BRAF kinase inhibitor vemurafenib, both of which significantly improved overall survival. Since then, availability of new immunotherapies, especially the anti-programmed death-1 checkpoint inhibitors, as well as other targeted therapies, have further improved outcomes for patients with advanced melanoma. Seven years on from the first approval of these novel therapies, evidence for the use of various immune-based and targeted approaches is continuing to increase at a rapid rate. Improved understanding of the tumour microenvironment and tumour immuno-evasion strategies has resulted in different approaches to target and harness the immune response. These new immune-based approaches offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities such as targeted therapy, electrochemotherapy and surgery. The increasing number of treatment options that are now available has resulted in a growing need to identify which patients will derive most benefit from which treatments. Much research is now focused on the identification of biomarkers that can be utilised to help select patients for treatment. These and other recent advances in the management of melanoma were the focus of discussions at the third Melanoma Bridge meeting (30 November–2 December, 2017, Naples, Italy), which is summarised in this report.Keywords
This publication has 48 references indexed in Scilit:
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapyOncoImmunology, 2014
- Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasisBMC Cancer, 2013
- Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T CellsScience Translational Medicine, 2013
- Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma MetastasisJournal of Clinical Oncology, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialThe Lancet, 2008
- Treatments for metastatic melanoma: Synthesis of evidence from randomized trialsCancer Treatment Reviews, 2007